macro

Implantica gets FDA approval for U.S. launch, but clinic training will pace revenue

Implantica's third-quarter sales rose 105% to EUR 748,000. The company won FDA approval, but paid U.S. procedures depend on clinic onboarding and staff training.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to TradingView, Implantica's third-quarter sales grew 105% year on year to EUR 748,000. Its adjusted gross margin reached 94%, and cash plus short-term investments stood at EUR 38.3 million.

FDA approval has made a commercial launch in the United States possible. Paid procedures will only begin once centers are onboarded and medical staff are trained, so the effect on revenue is likely to build gradually.

why it matters

For investors, the key question is how quickly American clinics can start performing procedures. Until onboarding is complete, revenue from the new market will stay limited, and the market will likely watch the pace of center additions in upcoming reports.

market impact

Implantica: FDA approval opens U.S. sales, but revenue depends on clinic onboarding

tags

instruments

Implantica

sources

  1. Implantica: FDA approval opens the U.S. launch; training and center approvals pace near-term revenue — TradingView, 19 November 2026 at 16:30 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗